WADA - WADA Technical Document – ISL TD2027ATP

WADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 1/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 Analytical Testing Procedures 1.0 Introduction This Technical Document (TD), which constitutes an integral part of the International Standard for Laboratories (ISL [1]), establishes the framework for the application of Analytical Testing Procedures (ATPs) for Doping Control. The intent is to ensure consistency and transparency in the implementation of ATPs across all Laboratories, including WADA-accredited Laboratories (i.e., Laboratories) and, where applicable, Laboratories approved to analyze whole blood Samples for the Markers of the Hematological Module of the Athlete Biological Passport (ABP) (i.e., ABP Laboratories). ATPs include mandatory and non-mandatory Analytical Methods. 2.0 Analytical Testing Procedures ATPs are a fundamental part of D oping Control, enabling the Laboratories to reliably detect, identify, and/or quantify specific Analytes in Samples. ATPs, also referred to as Analytical Methods or Test Methods, are carried out in accordance with the requirements established in the WADA International Standard for Laboratories (ISL) [1] and its associated ISL TDs (e.g., see ISL TD VAL [2]) and ISL Technical Letters (TLs). 2.1 Fitness-for-Purpose: Validation and ISO Accreditation of ATPs The Fitness-for-Purpose of ATPs shall be demonstrated through method validation in conformity with ISO/IEC 17025 [3] (or ISO 15189 [4], as applicable to ABP Laboratories) and ISL [1] requirements, including its applicable ISL TDs and ISL TLs.

The Fitness-for-Purpose of ATPs shall be demonstrated through method validation in conformity with ISO/IEC 17025 [3] (or ISO 15189 [4], as applicable to ABP Laboratories) and ISL [1] requirements, including its applicable ISL TDs and ISL TLs. Irrespective of whether an ATP is mandatory or not, it shall be validated and should be included within the Laboratory’s Scope of ISO/IEC 17025 Accreditation [3] (or ISO 15189 [4], as applicable to ABP Laboratories) before it can be applied for the analysis and reporting of analytical results [either as Negative Findings, Adverse Analytical Findings (AAFs) or Atypical Findings (ATFs)] for Samples. Whenever possible, the ATP should be subjected to the evaluation of method performance through the Laboratory’s participation in the WADA External Quality Assessment Scheme (EQAS) or other inter-Laboratory collaborative studies. [Comment to Article 2.1: Laboratories may analyze Samples using open-profiling screening assays (untargeted screening strategies) without having completed the validation of the procedures according to the requirements of ISL TD VAL. However, results can only be reported as an AAF or ATF after being confirmed using a CP that has been validated in accordance with ISL TD VAL [2].] As established in the ISL [1], under exceptional circumstances, and upon informing WADA , a Laboratory may apply a validated ATP to the analysis of Samples before its inclusion into the Laboratory’s Scope of ISO/IEC 17025 Accreditation. However, in such cases, the Laboratory would not automatically benefit from the presumption that the Test Method is valid and, consequently, the Laboratory may be required to provide Test M ethod validation documentation or EQAS performance data in support of a reported AAF or ATF.WADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group

Approved by: WADA Executive Committee

Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 2/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 2.2 Classification of Analytical Testing Procedures 2.2.1 Mandatory ATPs (see Table 1) All Laboratories shall have the mandatory ATPs (Initial Testing Procedures (ITPs) and Confirmation Procedures (CPs), where applicable) included within their Scope of ISO/IEC 17025 Accreditation [3] (or ISO 15189 [4], as applicable to ABP Laboratories). Mandatory ATPs shall be applied to: a) All Samples collected, both In-Competition (IC) and Out-of-Competition (OOC) (i.e., for the analysis of Prohibited Substance(s) and/or Prohibited Method(s) that are prohibited at all times) (see Table 1A), or b) All Samples collected IC only (for Prohibited Substances that are prohibited IC only) (see Table 1B), or c) All Samples collected in specific sports (for Prohibited Substances that are banned only in those sports) (see Table 1C). d) In cases of temporary disruption of Laboratory analytical capacity, these mandatory ATPs may be subcontracted to other Laboratories. 2.2.2 Additional Mandatory ATPs (see Table 2) a) These ATPs shall be applied upon request by the Testing Authority (TA) or Results Management Authority (RMA, if different)/ Athlete Passport Management Unit (APMU) or WADA, or shall be applied as mandatory CPs, as required. b) All Laboratories shall have the additional mandatory ATPs (ITPs and CPs, where applicable), included within their Scope of ISO/IEC 17025 Accreditation [3].

WADA, or shall be applied as mandatory CPs, as required. b) All Laboratories shall have the additional mandatory ATPs (ITPs and CPs, where applicable), included within their Scope of ISO/IEC 17025 Accreditation [3]. c) In cases of temporary disruption of Laboratory analytical capacity, these mandatory ATPs may be subcontracted to other Laboratories. 2.2.3 Non-mandatory ATPs (see Table 3). a) The implementation of a non-mandatory ATP by a Laboratory is optional. Therefore, not all Laboratories would have the nonmandatory ATPs within their Scope of ISO/IEC 17025 Accreditation [3]. b) These Analytical Methods may be subcontracted to other Laboratories or to WADAapproved laboratories (except for the analysis of the Markers of the Hematological Module of the ABP, due to the limited time requirements for such analysis – see also ISL [1] and ISL TD HEM [5]).WADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 3/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 The classification of an ATP as either mandatory or non-mandatory is not static. A non-mandatory ATP can become mandatory (or vice versa) depending on several factors, including but not limited to, the prevalence of Use of the Prohibited Substance(s) or Prohibited Method(s), numbers of Samples collected for analysis by Anti-doping Organizations (ADOs), ease of Laboratory access to instrumentation/technology or Reference Materials (RMs), technological and/or analytical complexity of the Test Method, availability of national/regional access to the Test Method , or analytical costs.

Samples collected for analysis by Anti-doping Organizations (ADOs), ease of Laboratory access to instrumentation/technology or Reference Materials (RMs), technological and/or analytical complexity of the Test Method, availability of national/regional access to the Test Method , or analytical costs. Therefore, considering the developments in the Laboratory’s capacity to implement non-mandatory ATPs, the Laboratory shall report and maintain in ADAMS an up-to-date list of available ATPs and services [1]. In addition, upon request by an ADO , the Laboratory should cooperate by providing other relevant information (e.g., Laboratory analytical capabilities or prices for analytical services) to assist the ADO with their Testing plans. [Comment to Article 2.2: Given the dynamic nature of the classification of ATPs as either mandatory or non-mandatory, as well as the continuous development of new ATPs for Doping Control, this ISL TD ATP may require frequent updates. For avoidance of doubt, Laboratories are not constrained from implementing a new non-mandatory ATP or from applying an approved ATP in a new matrix of analysis not listed in this ISL TD ATP as long as that new ATP / matrix of analysis has been demonstrated to be Fit-for-Purpose through method validation (in conformity with ISO/IEC 17025 and ISL requirements, including its applicable ISL TDs and ISL TLs ). Under exceptional circumstances, and upon informing WADA, the Laboratory may apply the validated new ATP / matrix to the analysis of Samples before its inclusion into the Laboratory’s Scope of ISO/IEC 17025 Accreditation (see also Article 2.1 and ISL Article 4.1.4.2.4.] 2.3 Temporary Disruptions to Analytical Capacity Where a Laboratory cannot apply an ATP to the analysis of Samples due to, for example, a temporary disruption of its analytical capacity (e.g., instrumental or staffing issues) that may affect test results reporting timelines, the Laboratory shall inform its customers and WADA. Where a Laboratory’s inability to apply a mandatory ATP leads to the subcontracting of the analysis

temporary disruption of its analytical capacity (e.g., instrumental or staffing issues) that may affect test results reporting timelines, the Laboratory shall inform its customers and WADA. Where a Laboratory’s inability to apply a mandatory ATP leads to the subcontracting of the analysis for Samples already received at the Laboratory , the Laboratory shall bear the costs of Sample transportation to the subcontracted Laboratory(-ies) as well as any additional analytical costs, unless otherwise agreed with the responsible TA. 3.0 WADA-specific Analytical Testing Procedures WADA-specific ATPs (see Table 4) , which are applied by Laboratories for the analysis of certain Prohibited Substance s and Prohibited Methods , require specific implementation steps prior to their application to Samples (see Appendix 1): a) Application of Flexible Scope of ISO/IEC 17025 Accreditation is not allowed for the WADA-specific ATPs, even if the addition of the proposed Test Method would fall within the boundaries of allowed flexibility [6]. b) Therefore, in such cases, the Laboratory shall validate the WADA-specific ATP and inform WADA before requesting an extension to the ir Scope of ISO/IEC 17025 Accreditation by the relevantWADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 4/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 Accreditation Body (AB). The Laboratory may also be required to successfully participate in an interlaboratory collaborative study or WADA-organized EQAS round (see ISLTD EQAS [6]). c) An a ssessment of WADA-specific ATPs by an AB is required for an extension of the Scope of ISO/IEC 17025 [3] Accreditation before application of the Test Method to the analysis of Samples.

c) An a ssessment of WADA-specific ATPs by an AB is required for an extension of the Scope of ISO/IEC 17025 [3] Accreditation before application of the Test Method to the analysis of Samples. d) However, once included within the Scope of ISO/IEC 17025 Accreditation, limited changes to these Test Methods can be made within the allowed boundaries of flexibility.

For example:

1. A Laboratory that has an accredited method ( e.g., LC-MSn) for the quantification of Threshold Substances may include a new Threshold Substance within the Flexible Scope of ISO/IEC 17025

Accreditation if this new Threshold Substance and its applicable Decision Limit (DL) is defined in the ISL TD DL [7] or another relevant ISL TD or ISL TL. ii. A Laboratory that has an accredited WADA-specific Test Method for the analysis of a specific type of substances (e.g., LC-MSn for the analysis of insulins), may include additional analogs of the substance into the Test Method within the Flexible Scope of ISO/IEC 17025 Accreditation. e) Nonetheless, this flexibility does not allow the Laboratory to introduce new Analytes into these Test Methods if specific compliance decision criteria (applicable to these new Analytes) are required but are not yet defined in an applicable ISL TD or ISL TL.

For example:

1. New Target Compounds (TCs) or Endogenous Reference Compounds (ERCs) for GC/C/IRMS analysis shall not be flexibly included within the accredited GC/C/IRMS Test Method if specific method performance characteristics [e.g., Limit of Quantification (LOQ), Measurement Uncertainty (MU)] and compliance decision criteria (e.g., DL) for the new Analyte have not been established in the ISL TD IRMS [8] or another relevant ISL TD or ISL TL. In such cases, the Laboratory shall request the AB for an extension to the method’s scope to include the new Analyte within the Scope of ISO/IEC 17025 Accreditation [3].

established in the ISL TD IRMS [8] or another relevant ISL TD or ISL TL. In such cases, the Laboratory shall request the AB for an extension to the method’s scope to include the new Analyte within the Scope of ISO/IEC 17025 Accreditation [3]. ii. In contrast, if analytical and compliance requirements for these Analytes have been defined in a ISL TD or ISL TL, then the Laboratory may include them into the accredited GC/C/IRMS Test Method within the allowed boundaries of flexibility.WADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 5/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 Table 1. List of Mandatory Analytical Testing Procedures

MANDATORY TEST METHODS

A. APPLICABLE TO ALL SAMPLES: INand OUT-OF-COMPETITION

Prohibited Substance Class Prohibited Substance Subclass / Specific Examples Matrix Test Method(s) 1, 2, 3 Exceptions (not mandatory) Qualitative Procedure Quantitative Procedure S1. Anabolic Agents S1.1 Anabolic Androgenic Steroids (AAS) • Exogenous AAS • 19-NA; 19-NE Urine ITP and CP: GC-MSn or LC-MSn n/a n/a 4 • Urinary Markers of the Steroidal Module of the ABP 5 CP: GC-MSn ITP and CP: GC-MSn S1.2 Other Anabolic Agents Urine ITP and CP: GC-MSn or LC-MSn n/a n/a

• Urinary Markers of the Steroidal Module of the ABP 5 CP: GC-MSn ITP and CP:

GC-MSn S1.2 Other Anabolic Agents Urine ITP and CP: GC-MSn or LC-MSn n/a n/a

1 Where an “n” is indicated for mass spectrometric (MS) methods, n ≥ 1. 2 The listing of chromatographic-mass spectrometric Test Methods (e.g., GC-MSn, LC-MSn) shall not be interpreted as a restriction to the use of gas- (GC) or liquid chromatography (LC) methods. Other chromatographic Test Methods, such as, for example, Supercritical Fluid Chromatography (SFC) may also be applied if they have been validated and included in the Laboratory’s Scope of ISO/IEC 17025 Accreditation. 3 If not specified, the Test Method applies to both ITP and CP. 4 n/a: Not applicable 5 This ATP is also considered a WADA-specific ATP. Refer to Table 4 - WADA-specific ATPs.WADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 6/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 Prohibited Substance Class Prohibited Substance Subclass / Specific Examples Matrix Test Method(s) 1, 2, 3 Exceptions (not mandatory) Qualitative Procedure Quantitative Procedure S2. Peptide Hormones, Growth Factors, Related Substances, and Mimetics S2.1.2 Hypoxia-inducible Factor (HIF) Activating Agents Urine ITP and CP:

(not mandatory) Qualitative Procedure Quantitative Procedure S2. Peptide Hormones, Growth Factors, Related Substances, and Mimetics S2.1.2 Hypoxia-inducible Factor (HIF) Activating Agents Urine ITP and CP: LC-MSn or GC-MSn n/a Xenon (GC-MS) Cobalt (ICP-MS) S2.2.1 Chorionic gonadotrophin (CG) 5, 6 Urine n/a ITP for hCG: Immunoassay or LC-MSn CP for hCG (Quantitative Procedure): Immunoassay 7 or LC-MSn S3. Beta-2 Agonists Urine Non-Threshold Substances (ITP, CP) LC-MSn, or GC-MSn

Threshold Substances (ITP, CP) LC-MSn or GC-MSn n/a

Threshold Substances (CP) LC-MSn or GC-MSn n/a

6 Testing for hCG is applicable only to Samples from male Athletes or when a test for pregnancy is needed on Samples from female Athletes in accordance with the ISL TD NA [9]. 7 If the Laboratory uses immunoassays specific for the α/β heterodimer of hCG for both the ITP and the CP, then the confirmation immunoassay shall be different from the immunoassay applied for the ITP [10].WADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 7/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 Prohibited Substance Class Prohibited Substance Subclass / Specific Examples Matrix Test Method(s) 1, 2, 3 Exceptions (not mandatory) Qualitative Procedure Quantitative Procedure S4. Hormone and Metabolic Modulators S4.1 Aromatase Inhibitors Urine ITP and CP: LC-MSn or GC-MSn n/a n/a S4.2 Anti-estrogenic Substances Urine ITP and CP: LC-MSn or GC-MSn n/a n/a S4.4.1 Activators of the AMP-activated protein kinase (AMPK) and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists Urine ITP and CP: LC-MSn or GC-MSn n/a n/a S4.4.3 Meldonium Urine ITP and CP: LC-MSn n/a n/a S4.4.4 Trimetazidine Urine ITP and CP: LC-MSn or GC-MSn n/a n/a S5. Diuretics and Masking Agents

• Diuretics Urine ITP and CP: LC-MSn or GC-MSn n/a n/a • Masking Agents Other plasma expanders pH Urine Electrochemistry pH strips n/a n/a

Specific Gravity (SG) Urine n/a

ITP: Densitometry

ITP and CP: Refractometry

n/a • Masking Agents Other plasma expanders pH Urine Electrochemistry pH strips n/a n/a Specific Gravity (SG) Urine n/a

ITP: Densitometry

ITP and CP: Refractometry

n/aWADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 8/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 Prohibited Substance Class Prohibited Substance Subclass / Specific Examples Matrix Test Method(s) 1, 2, 3 Exceptions (not mandatory) Qualitative Procedure Quantitative Procedure

B. APPLICABLE TO IN-COMPETITION SAMPLES

S6. Stimulants Urine

ITP and CP: LC-MSn or GC-MSn

Threshold Substances (ITP, CP) LC-MSn, or GC-MSn

Threshold Substances (CP) GC-NPD, or LC-MSn, or GC-MSn n/a S7. Narcotics Urine

ITP and CP: LC-MSn or GC-MSn

Threshold Substances (ITP, CP) LC-MSn or GC-MSn

Threshold Substances CP) LC-MSn or GC-MSn n/a S8. Cannabinoids Urine

ITP and CP: LC-MSn or GC-MSn

Threshold

Threshold Substances CP) LC-MSn or GC-MSn n/a S8. Cannabinoids Urine

ITP and CP: LC-MSn or GC-MSn

Threshold Substances (ITP, CP) LC-MSn or GC-MSn

Threshold Substances CP) LC-MSn or GC-MSn n/a S9. Glucocorticoids Urine ITP and CP: LC-MSn or GC-MSn n/a n/aWADA Technical Document – ISL TD2027ATP

Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 10/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 Table 2. List of Additional Mandatory Analytical Testing Procedures

ADDITIONAL MANDATORY TEST METHODS

(WHEN REQUESTED BY TESTING AUTHORITIES / APMU or AS MANDATORY CONFIRMATION PROCEDURES)

Prohibited Substance Class Prohibited Substance Subclass / Specific Examples Matrix Test Method(s) 1, 2, 3 Exceptions (not mandatory) Qualitative Procedure Quantitative Procedure S1. Anabolic Agents S1.1 Anabolic Androgenic Steroids (AAS) • Urinary Markers of the Steroidal Module of the ABP Urine n/a CP: GC/C/IRMS 5 n/a S2. Peptide Hormones, Growth Factors, Related Substances, and Mimetics S2.1.1 Erythropoietin Receptor Agonists (ERAs) 5

• Recombinant EPOs, NESP, CERA, EPO-Fc.

Urine Plasma Serum

ITP and CP: PAGE Method [12] n/a EPO-mimetic agents

(e.g., CNTO-530, Peginesatide) S2.2.1 GnRH ,8 and its agonist analogues Urine ITP and CP: LC-MSn n/a n/a S2.2.3 Growth Hormone • hGH Isoforms Test 5 Serum n/a Immunoassay n/a

S2.2.3 Growth Hormone

LC-MSn n/a n/a S2.2.3 Growth Hormone • hGH Isoforms Test 5 Serum n/a Immunoassay n/a

S2.2.3 Growth Hormone Fragments (AOD-9604, hGH 176-191)

Urine

ITP and CP: LC-MSn n/a n/a

8 Testing for GnRHs is applicable only to Samples from male Athletes.WADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 11/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 Prohibited Substance Class Prohibited Substance Subclass / Specific Examples Matrix Test Method(s) 1, 2, 3 Exceptions (not mandatory) Qualitative Procedure Quantitative Procedure S2. Peptide Hormones, Growth Factors, Related Substances, and Mimetics (continued) S2.2.4 Growth Hormone Releasing Factors Growth Hormone Secretagogues (GHS) and Growth Hormone Releasing Peptides (GHRPs) Urine

ITP and CP:

LC-MSn

n/a n/a S2.3 Growth Factors and Growth Factor Modulators TB-500 S5. Diuretics and Masking Agents Masking Agent(s) • Desmopressin , Felypressin Urine ITP and CP: LC-MSn or GC-MSn n/a n/a These are often referred to as “small peptides”WADA Technical Document – ISL TD2027ATP

Agents Masking Agent(s) • Desmopressin , Felypressin Urine ITP and CP: LC-MSn or GC-MSn n/a n/a These are often referred to as “small peptides”WADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 12/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 Table 3. List of Non-Mandatory Analytical Testing Procedures

NON-MANDATORY (OPTIONAL) TEST METHODS

Prohibited Substance Class Prohibited Substance Subclass / Specific Examples Matrix Test Method(s) 1, 2, 3 Qualitative Procedure Quantitative Procedure Relevant Target Analytes • 6α-Hydroxy-androstenedione (6α-OH-AD) • 19-NA, 19-NE • Boldenone and Boldenone Metabolite(s) • Epiandrosterone sulfate

• Formestane

Urine n/a CP:

GC/C/IRMS 5

S1. Anabolic Agents S1.1 Anabolic Androgenic Steroids (AAS)

• Steroid Esters Serum, Plasma

DBS ITP and CP: LC-MSn or GC-MSn n/a • Blood Markers of the Steroidal Module of the ABP 5 Serum

DBS CP: LC-MSn ITP/CP:

LC-MSn • Exogenous AAS DBS 9 ITP and CP: LC-MSn or GC-MSn n/a

• Blood Markers of the Steroidal Module of the ABP 5 Serum

DBS CP: LC-MSn ITP/CP:

LC-MSn • Exogenous AAS DBS 9 ITP and CP: LC-MSn or GC-MSn n/a

9 DBS Testing can only be applied to Non-Threshold Substances without MRL [13]WADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 13/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 Prohibited Substance Class Prohibited Substance Subclass / Specific Examples Matrix Test Method(s) 1, 2, 3 Qualitative Procedure Quantitative Procedure

S2. Peptide Hormones, Growth Factors, Related Substances, and Mimetics

S2.1.1 Erythropoietin Receptor Agonists (ERAs) 5 Urine

DBS ITP and CP: PAGE Methods [12] or LC-MSn n/a S2.1.2 Hypoxia-inducible Factor (HIF) Activating Agents DBS ITP and CP: LC-MSn n/a

S2.1.2 Hypoxia-inducible Factor (HIF) Activating Agents

• Cobalt
• Xenon

Urine n/a ITP and CP:

ICP-MS or GC-MS

S2.1.4 TGFβ Signaling Inhibitors Urine Serum, Plasma DBS

ITP and CP:

• Cobalt
• Xenon

Urine n/a ITP and CP:

ICP-MS or GC-MS

S2.1.4 TGFβ Signaling Inhibitors Urine Serum, Plasma

DBS ITP and CP: PAGE Methods [12] or LC-MSn n/a

S2.1.5 Innate Repair Receptor Agonists

• Asialo EPO
• Carbamylated EPO

Urine ITP and CP: PAGE Methods n/a S2.2.1 • Intact hCG 5, 6, 7 Urine n/a CP: Immunoassay or LC-MSn • LH 5, 10 n/a ITP: Immunoassay S2.2.1 GnRH ,8 and its agonist analogues DBS ITP and CP: LC-MSn

10 Testing for LH is applicable only to Samples from male Athletes.WADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 14/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 Prohibited Substance Class Prohibited Substance Subclass / Specific Examples Matrix Test Method(s) 1, 2, 3 Qualitative Procedure Quantitative Procedure S2. Peptide Hormones, Growth Factors, Related Substances, and Mimetics (Continued)

S2.2.2 Corticorelin, Tetracosactide Urine, DBS ITP and CP: LC-MSn n/a S2.2.3 Growth Hormone, its Analogues and Fragments

and Mimetics (Continued)

S2.2.2 Corticorelin, Tetracosactide Urine, DBS ITP and CP: LC-MSn n/a S2.2.3 Growth Hormone, its Analogues and Fragments

hGH Biomarkers Test 5 Serum IGF-I (CP): LC-MSn P-III-NP (ITP, CP): immunoassay IGF-I (ITP, CP): Immunoassay or

LC-MSn

(bottom-up) hGH Analogues (Somatrogon) Urine Serum, Plasma CP: LC-MSn ITP: hGH isoforms test kit 2 Blood Markers of the Endocrine Module of the ABP 5 Serum IGF-I (CP): LC-MSn

P-III-NP (ITP, CP):

Siemens Centaur Immunoassay

IGF-I (ITP, CP):

LC-MSn

(top down) S2.2.4 Growth Hormone-Releasing Factors Growth Hormone-Releasing Hormone (GHRH) and its analogues 5 Urine Serum, Plasma ITP and CP: LC-MSn n/a Growth Hormone Secretagogues (GHS) and Growth Hormone Releasing Peptides (GHRPs) Serum, Plasma DBS ITP and CP: LC-MSn n/a S2.3 Growth Factors and Growth Factor Modulators 5 • IGFI and its analogues

• Mechano Growth Factors

Urine Serum, Plasma DBS ITP and CP: LC-MSn n/a • TB-500 DBS ITP and CP: LC-MSn n/aWADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

• TB-500 DBS ITP and CP: LC-MSn n/aWADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 15/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 Prohibited Substance Class Prohibited Substance Subclass / Specific Examples Matrix Test Method(s) 1, 2, 3 Qualitative Procedure Quantitative Procedure S3. Beta-2 Agonists DBS ITP and CP: LC-MSn or GC-MSn n/a S4. Hormone and Metabolic Modulators S4.1 Aromatase Inhibitors DBS ITP and CP: LC-MSn or GC-MSn n/a S4.2 Anti-estrogenic Substances DBS ITP and CP: LC-MSn or GC-MSn n/a S4.3 Agents Preventing Activin Receptor IIB Activation e.g., Bimagrumab Urine Serum, Plasma

ITP and CP: LC-MSn or PAGE Methods n/a S4.4.1 Activators of the AMP-activated Protein Kinase (AMPK) and Peroxisome Proliferator Activated Receptor δ (PPARδ) Agonists DBS ITP and CP: LC-MSn or GC-MSn n/a S4.4.2 Metabolic Modulators Insulins and insulin-mimetics , 5

Urine Serum, Plasma

DBS ITP and CP: LC-MSn n/a

LC-MSn or GC-MSn n/a S4.4.2 Metabolic Modulators Insulins and insulin-mimetics , 5 Urine Serum, Plasma

DBS ITP and CP: LC-MSn n/a

S4.4.4 Trimetazidine DBS ITP and CP: LC-MSn or GC-MSn n/a S5. Diuretics and Masking Agents Diuretics DBS

ITP and CP: LC-MSn or GC-MSn n/a

Masking Agent(s) • Desmopressin , Felypressin DBS n/a Plasma Expanders • Dextran, HES, Mannitol Urine n/aWADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 16/20 ISL TD2027ATP – Version 1.0 – 01 January 2027 Prohibited Substance Class Prohibited Substance Subclass / Specific Examples Matrix Test Method(s) 1, 2, 3 Qualitative Procedure Quantitative Procedure M1. Manipulation of Blood and Blood Components

M1.1 • Homologous Blood Transfusion (HBT) 5 Whole blood n/a ITP and CP: Flow Cytometry • Markers of the Hematological Module of the ABP 5, 11 Whole blood n/a ITP and CP: Flow Cytometry • Phthalates (DEHP Metabolites) Urine ITP and CP: LC-MSn n/a M1.2

Flow Cytometry • Markers of the Hematological Module of the ABP 5, 11 Whole blood n/a ITP and CP: Flow Cytometry • Phthalates (DEHP Metabolites) Urine ITP and CP: LC-MSn n/a M1.2 • Efaproxiral (RSR 13) Urine, DBS ITP and CP: LC-MSn n/a • HBOCs 5 Serum, Plasma Whole blood

ITP: Visual inspection

Spectrophotometry (serum/plasma)

ITP and CP: Native-PAGE; or

Capillary Electrophoresis; or Flow Cytometry; or LCMSn n/a • Myo-inositol Trispyrophosphate (ITPP) Urine Serum, Plasma DBS ITP and CP: LC-MSn n/a

11 Due to the requirements to analyze ABP Samples within timelines that meet the Blood Stability Score (BSS) criteria, the analysis of the Markers of the Hematological Module of the ABP is an ATP that cannot be subcontracted.WADA Technical Document – ISL TD2027ATP Document number: ISL TD2027ATP Version number: 1.0

Written by:

Reviewed by: WADA Science

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2